
Healthcare major Manipal Health Enterprises Ltd reported a 10.3% year-on-year decline in net profit to ₹285 crore for Q2 FY27, compared with ₹318 crore in the corresponding quarter last year. According to the company's investor presentation, revenue from operations showed strong growth of 37.3% year-on-year to ₹3,399 crore in the September quarter, compared with ₹2,475 crore a year ago. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 29.8% to ₹882 crore from ₹680 crore in the year-ago period, though the EBITDA margin contracted to 26% in the second quarter compared with 27.5% in the corresponding quarter of the previous financial year. The decline in reported profit was primarily attributed to a ₹95 crore exceptional loss during the quarter, compared with an exceptional gain of around ₹5 crore in the corresponding period last year.
Following the Q2 results, brokerages turned increasingly constructive on Manipal Health, with JPMorgan upgrading the stock to 'Overweight' from 'Neutral' and raising its target price to ₹820 from ₹800. The brokerage cited faster-than-expected integration of Sahyadri Hospitals and improving occupancy levels as key drivers supporting stronger profitability and operating leverage. HSBC maintained its 'Buy' rating with a target price of ₹880, raising FY27, FY28 and FY29 earnings estimates by 6.9%, 1.8% and 1.1% respectively, while Jefferies reiterated its 'Buy' recommendation with a target price increased to ₹900 from ₹870. Kotak Institutional Equities maintained its 'Add' rating and raised its target price to ₹760 from ₹730, forecasting revenue and EBITDA compound annual growth rates of about 17% and 20% respectively over FY26-FY29.
Operating performance during the quarter was supported by significant growth in patient volumes and occupancy. According to the company's investor presentation, inpatient volumes increased 35% to approximately 169,000, while outpatient volumes rose 27.2% to around 1.74 million. Occupancy improved 160 basis points year-on-year to 70.1% from 68.5% a year ago, with average operational capacity of 7,331 beds and an average length of stay of 2.8 days. The company opened its 300-licensed-bed Electronic City hospital in Bengaluru during the quarter, taking its total licensed bed capacity to 13,440 as of September 30, 2026. Consolidated average revenue per occupied bed (ARPOB) remained stable at ₹70,600 per day on a consolidated basis, with net debt excluding lease liabilities at ₹343 crore at the end of the quarter.
Sahyadri Hospitals contributed ₹375 crore in revenue and ₹73 crore in EBITDA during Q2 FY27, with revenue standing at ₹707 crore for H1 FY27, up 17.8%, while EBITDA increased 24.1% to ₹131 crore. As reported by CNBC TV18, Sahyadri's occupancy for the first half stood at 67%, improving 270 basis points year-on-year, while ARPOB increased 12.5% to ₹44,100 per day. The integration process progressed with the rollout of centralised procurement rates and the addition and enhancement of clinical capabilities. HSBC noted that Manipal plans to add 550-600 beds through FY28 and is also evaluating a new 500-bed hospital in Gurugram. Kotak expects approximately 2,400 new beds to be added in the coming years, with nearly 40% of the additions concentrated in core markets.
The company's six CONGO-R Centres of Excellence — Cardiac Sciences, Oncology, Neurosciences, Gastroenterology, Orthopaedics and Renal Sciences — continued to support high-acuity care across the network. According to CNBC TV18, during H1 FY27, oncology revenue grew 51% year-on-year, while neurosciences revenue increased 47% and orthopaedics grew 44%. Cardiac sciences, gastroenterology and renal sciences recorded revenue growth of 39%, 36% and 38%, respectively. Jefferies highlighted that Sahyadri's margins improved by 200 basis points sequentially as integration efforts progressed, while the company's expansion pipeline remains on track. Managing Director and CEO Dilip Jose stated that the quarter's growth was driven by patient volumes, improved capacity utilisation and increasing contributions from high-acuity specialties.
Shares of Manipal Health Enterprises Ltd ended at ₹681.40, up by ₹4.90 or 0.72%, on the BSE following the results announcement. The stock opened at ₹675.20 and moved in the range of ₹671.15 to ₹693.00 during the trading session. Looking at its last 52-week performance, the stock has touched a low of ₹597.00 and a high of ₹815.00, with the stock up 68% on a year-on-year basis. Kotak noted that Manipal's relatively low oncology mix limits the impact of the government's 30% trade-margin cap on oncology drugs, though any future expansion of the cap to medical consumables remains a monitorable risk. Overall, brokerages remain positive on Manipal Health's ability to sustain growth through capacity additions, improving occupancy levels and successful integration of recent acquisitions, making it one of the preferred plays in India's hospital sector.